Metronomic Chemotherapy: Direct Targeting of Cancer Cells after all?

Nicolas André, Kelvin Tsai, Manon Carré, Eddy Pasquier

Research output: Contribution to journalReview articlepeer-review

41 Citations (Scopus)


Metronomic chemotherapy (MC) was initially described as an antiangiogenic therapy more than 15 years ago. Over the past few years, additional data have highlighted the impact of MC on the microenvironment beyond angiogenesis, with, most importantly, a potential impact on the immune system. Here, we review and reappraise the fact that MC might be able to directly kill cancer cells. Although long neglected, this question is of critical importance both fundamentally and clinically, especially when considering future associations with immunotherapies.

Original languageEnglish
Pages (from-to)319-325
Number of pages7
JournalTrends in Cancer
Issue number5
Publication statusPublished - May 1 2017


  • angiogenesis
  • chemotherapy
  • immunity
  • metronomic chemotherapy
  • stem cells

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Metronomic Chemotherapy: Direct Targeting of Cancer Cells after all?'. Together they form a unique fingerprint.

Cite this